All content for Oncology Brothers: Practice-Changing Cancer Discussions is the property of Oncology Brothers and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Managing Toxicities of Tyrosine Kinase Inhibitors (TKI) in CML - Drs. Onyee Chan & Fadi Haddad
Oncology Brothers: Practice-Changing Cancer Discussions
21 minutes
2 weeks ago
Managing Toxicities of Tyrosine Kinase Inhibitors (TKI) in CML - Drs. Onyee Chan & Fadi Haddad
In this episode of the Oncology Brothers podcast, we are joined by esteemed hematologists Dr. Onyee Chan from Moffitt Cancer Center and Dr. Fadi Haddad from MD Anderson to discuss the management of side effects associated with tyrosine kinase inhibitors (TKIs) used in the treatment of chronic myeloid leukemia (CML).
Join us as we delve into:• An overview of the different generations of TKIs, including imatinib, dasatinib, nilotinib, bosutinib, ponatinib, and asciminib.• Common class-wide toxicities such as fatigue, hypertension, gastrointestinal symptoms, and cytopenias.• Unique side effects associated with each TKI and strategies for dose optimization.• The importance of patient education and monitoring to ensure effective management of side effects.
Don't forget to check out our other ToxCheck episodes on antibody drug conjugates, CAR-T therapies, and more!
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/
Subscribe to the Oncology Brothers for more discussions on bridging the gap between academic research and community practice in cancer care!
#CML #TKI #ToxCheck #Hematology #OncologyBrothers #PrecisionMedicine
Oncology Brothers: Practice-Changing Cancer Discussions
